Over the weekend, Bristol Myers Squibb & Co BMY shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases.Data were presented at the American College of Rheumatology 2024.Also Read: Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee IssueCC-97540 (BMS-986353) is an investigational CD19-targeted CAR T cell therapy that expresses ...

Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the third cohort in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being cond ...

27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Patient Treated with Fludarabine-free Conditioning and Single-dose FT819; Favorable Safety Profile with No Grade ≥3 Adverse Events and No Events of CRS, ICANS, or GvHD Reconstituted B Cell Compartment Predominantly Consists of Naïve, Non-class Switched B Cells with Deep Depletion of Aberrant B Cells and Plasmablas ...

Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncologyAdvancing innovative strategies to overcome the unique challenges of applying CAR-T to solid tumorsVirtual R&D Day featuring partner Astellas Pharma and Poseida's lead ...

Avis Budget Group, Inc. (CAR) reported lower-than-expected third-quarter 2024 results.See Zacks Earnings Calendar to stay ahead of market-making news.Despite the earnings miss, the stock has gained 12% since the earnings release on Oct. 31, 2024.CAR’s earnings of $6.7 per share missed the Zacks Consensus Estimate by 22.2% and decreased 60.4% from the year-ago quarter’s actual. Total revenues of $3.5 billion missed the consensus estimate by 2.3% and declined 2.4% on a year-over-year basis.Avis Budget’s share ...

Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies Initial Low-Dose Cohort of FT825 / ONO-8250 as Monotherapy Shows Favorable Safety Profile in Phase 1 Solid Tumor Study Peripheral Blood from First Three Patients Demonstrates CAR T-cell Expansion with Maintenance of Activated State at Day 8 Following Treatment SAN DIEGO, Nov. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company ...

Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant Transformation Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy FT836 Preclinical Data Shows Robust Antigen-mediated Expansion, Functional Persistence, and Durable Anti-tumor Activity in the Presence of Alloreactive T Cells   SAN DIEGO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- ...

Note: All amounts discussed are in Canadian Dollars. Stock Prices refer to those on the TSX and not the OTC symbol. Canadian options are generally not accessible by USTrapping Value provides Covered Calls, and Preferred Stock Trader covers Fixed Income. The Covered Calls Portfolio is designed to provide lower volatility income investing with a focus on capital preservation. The fixed income portfolio focuses on buying securities with high income potential and heavy undervaluation relative to comparatives. L ...

Core Insights - Poseida Therapeutics is presenting new preclinical data on allogeneic CAR+TCR-T cells that are rich in stem cell memory T cells (TSCM) and have enhanced potency for targeting solid tumors at the SITC 39th Annual Meeting [1] - The company will also present additional profiling of patient responses from the P-BCMA-ALLO1 Phase 1 Arm C and preclinical data from P-CD19CD20-ALLO1 at the ASH Annual Meeting [2] Group 1: Product Development - P-BCMA-ALLO1 is an investigational non-viral TSCM-rich allogeneic CAR-T therapy currently in Phase 1/1b clinical development targeting BCMA for relapsed/refractory multiple myeloma [3] - P-CD19CD20-ALLO1 is the first allogeneic dual CAR-T cell product candidate targeting both CD19 and CD20 antigens for relapsed or refractory B-cell malignancies [3][8] - Both P-BCMA-ALLO1 and P-CD19CD20-ALLO1 are being developed in collaboration with Roche to address hematologic malignancies [3] Group 2: Upcoming Presentations - At SITC 2024, a poster presentation titled "Multi-antigen Targeting with CAR and TCR Co-expression in Allogeneic Cell Therapy for Solid Tumors" will be presented on November 9, 2024 [4] - At ASH 2024, multiple poster presentations will highlight clinical data from P-BCMA-ALLO1 and preclinical data from P-CD19CD20-ALLO1, scheduled for December 7-9, 2024 [5][6] Group 3: Regulatory Designations - P-BCMA-ALLO1 has received Orphan Drug designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for adult patients with relapsed/refractory multiple myeloma after three or more prior lines of therapies [6] - The investigational therapy is believed to address unmet needs in multiple myeloma, supported by interim clinical data [6] Group 4: Company Overview - Poseida Therapeutics is a clinical-stage biopharmaceutical company focused on advancing differentiated allogeneic cell therapies and genetic medicines [9] - The company utilizes proprietary genetic editing platforms and has formed strategic collaborations with Roche and Astellas to enhance cell therapy development [9]

Avis Budget didn't grow earnings in 2024, but 2025 looks better.Avis Budget Group (CAR 20.17%) stock is motoring higher today, its stock up 17.7% through 10:50 a.m. ET despite the rental car operator missing analyst forecasts for sales and earnings last night.Wall Street had predicted Avis would earn $8.18 per share on more than $3.5 billion in sales in Q3, but the company actually reported profits of only $6.65 per share, and sales just under $3.5 billion. Avis Q3 sales and earningsThat doesn't sound like ...